Biotech and Breakthroughs in Immuno-Oncology.

This article surveys the clinical development and investment activity with Immuno-Oncology, specifically prostate, kidney, and bladder cancers. PMID: 33008500 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33008500?dopt=Abstract

Source: The Urologic Clinics of North America - October 4, 2020 Category: Urology & Nephrology Authors: Bockman JM Tags: Urol Clin North Am Source Type: research

More News: Biotechnology | Bladder Cancer | Cancer | Cancer & Oncology | Urology & Nephrology